journal article·2023-10Open access

Medical Gas Plasma Technology Combines with Antimelanoma Therapies and Promotes Immune‐Checkpoint Therapy Responses

Lea Miebach, Gabriella Melo‐Zainzinger, Eric Freund, Ramona Clemen, Alessandra Lourenco Cecchini, Sander Bekeschus

Advanced Science· Volume 10· Issue 28

Abstract

Abstract Strategies to improve activity and selectivity are major goals in oncological drug development. Medical gas plasma therapy has been subject to intense research in dermatooncology recently. Based on partial gas ionization, this approach is exceptional in generating a variety of reactive oxygen species simultaneously that can be applied locally at the tumor side. It is hypothesized that combined gas plasma treatment can potentiate drug responses in the treatment of melanoma. Using a plasma jet approved as medical device in Europe, a systematic screening of 46 mitochondria‐targeted drugs identifies five agents synergizing in vitro and in vivo. Increased intratumoral leucocyte infiltration points to immunomodulatory aspects of the treatment, motivating to investigate responses to immune checkpoint blockade in combination with plasma. Tumor growth is monitored based on bioluminescent imaging, and single‐cell suspensions are retrieved from each tumor to characterize tumor‐infiltrating leucocytes using multicolor flow cytometry. Gene expression profiling is done using a validated NanoString panel targeting 770 genes specifically designed for immuno‐oncological research. Cell type abundancies are characterized from bulk RNA samples using the CIBERSORT computational framework. Collectively, the results indicate that local application of medical gas plasma technology synergizes with mitochondria‐targeted drugs and anti‐PD1 checkpoint therapy in treating melanoma.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Plasma Applications and Diagnostics · 3D Printing in Biomedical Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of General, Thoracic, Vascular, and Visceral Surgery Greifswald University Medical Center 17475 Greifswald Germany

ZIK plasmatis Leibniz Institute for Plasma Science and Technology (INP) 17489 Greifswald Germany

Cancer Research Unit Boehringer Ingelheim Vienna 1121 Austria

Department of Neurosurgery Wien University Medical Center Vienna 1090 Austria

Laboratory of Molecular Pathology State University of Londrina Londrina 86051‐990 Brazil

Clinic for Dermatology and Venerology Rostock University Medical Center 18057 Rostock Germany

References (92)

Show source-provided references
1. 10.1038/nature1181410.1038/nature11814 ↗
2. 10.1016/j.cell.2015.07.06110.1016/j.cell.2015.07.061 ↗
3. 10.1158/1078-0432.CCR-17-226710.1158/1078-0432.CCR-17-2267 ↗
4. 10.1038/s41591-019-0407-510.1038/s41591-019-0407-5 ↗
5. 10.1016/j.jid.2020.03.94310.1016/j.jid.2020.03.943 ↗
6. 10.1056/NEJM19940414330150110.1056/NEJM199404143301501 ↗
7. 10.1001/jama.2011.143710.1001/jama.2011.1437 ↗
8. 10.1038/s41571-021-00579-w10.1038/s41571-021-00579-w ↗
9. 10.1038/nrd280310.1038/nrd2803 ↗
10. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
11. 10.1088/1361-6463/ac5e1c10.1088/1361-6463/ac5e1c ↗
12. 10.1038/s41598-017-08560-310.1038/s41598-017-08560-3 ↗
13. 10.3390/cancers1209257010.3390/cancers12092570 ↗
14. 10.3390/cancers1011039410.3390/cancers10110394 ↗
15. 10.3390/cancers1207199310.3390/cancers12071993 ↗
16. 10.1038/cddis.2014.3310.1038/cddis.2014.33 ↗
17. 10.18632/oncotarget.540710.18632/oncotarget.5407 ↗
18. 10.1016/j.cpme.2015.02.00110.1016/j.cpme.2015.02.001 ↗
19. 10.1016/j.cpme.2017.09.00110.1016/j.cpme.2017.09.001 ↗
20. 10.1002/advs.20180206210.1002/advs.201802062 ↗
21. 10.1038/s41598-018-37169-310.1038/s41598-018-37169-3 ↗
22. 10.1002/advs.20200339510.1002/advs.202003395 ↗
23. 10.1116/6.000052910.1116/6.0000529 ↗
24. 10.1155/2017/427106510.1155/2017/4271065 ↗
25. 10.1038/s41598-018-31031-210.1038/s41598-018-31031-2 ↗
26. 10.3390/cancers1205128010.3390/cancers12051280 ↗
27. 10.3892/or.2016.503810.3892/or.2016.5038 ↗
28. 10.1016/j.freeradbiomed.2021.02.02610.1016/j.freeradbiomed.2021.02.026 ↗
29. 10.1111/pin.1266510.1111/pin.12665 ↗
30. 10.1038/bjc.2016.1210.1038/bjc.2016.12 ↗
31. 10.1038/s41598-019-49013-310.1038/s41598-019-49013-3 ↗
32. 10.1016/j.freeradbiomed.2017.04.36810.1016/j.freeradbiomed.2017.04.368 ↗
33. 10.1038/s41418-017-0012-410.1038/s41418-017-0012-4 ↗
34. 10.1016/S1470-2045(10)70261-810.1016/S1470-2045(10)70261-8 ↗
35. 10.1080/10428194.2020.184533210.1080/10428194.2020.1845332 ↗
36. 10.1200/JCO.2010.31.620810.1200/JCO.2010.31.6208 ↗
37. 10.1038/s41419-020-2646-210.1038/s41419-020-2646-2 ↗
38. 10.1111/pcmr.1224210.1111/pcmr.12242 ↗
39. 10.1158/1078-0432.CCR-10-235310.1158/1078-0432.CCR-10-2353 ↗
40. 10.1016/j.molcel.2015.05.03110.1016/j.molcel.2015.05.031 ↗
41. 10.1038/sj.onc.120752110.1038/sj.onc.1207521 ↗
42. 10.1016/j.ijcard.2015.02.01510.1016/j.ijcard.2015.02.015 ↗
43. 10.3390/cancers1413309710.3390/cancers14133097 ↗
44. 10.1371/journal.pone.006449810.1371/journal.pone.0064498 ↗
45. 10.1002/ppap.20140020710.1002/ppap.201400207 ↗
46. 10.3390/cells1011293610.3390/cells10112936 ↗
47. 10.1016/j.bbrc.2016.04.02710.1016/j.bbrc.2016.04.027 ↗
48. 10.1038/s41598-021-94130-710.1038/s41598-021-94130-7 ↗
49. 10.1002/ppap.20200023910.1002/ppap.202000239 ↗
50. 10.1038/s41419-018-1221-610.1038/s41419-018-1221-6 ↗
51. 10.3390/biom1007101110.3390/biom10071011 ↗
52. 10.3390/ijms2104137910.3390/ijms21041379 ↗
53. 10.7150/ijms.2010410.7150/ijms.20104 ↗
54. 10.1155/2021/299032610.1155/2021/2990326 ↗
55. 10.3390/nano1103080610.3390/nano11030806 ↗
56. 10.1371/journal.pone.016066710.1371/journal.pone.0160667 ↗
57. 10.3390/ijms1804086810.3390/ijms18040868 ↗
58. 10.3390/diagnostics1004021010.3390/diagnostics10040210 ↗
59. 10.1038/s41598-021-99924-310.1038/s41598-021-99924-3 ↗
60. 10.1016/j.ejcsup.2013.07.01310.1016/j.ejcsup.2013.07.013 ↗
61. 10.1038/s41573-018-0007-y10.1038/s41573-018-0007-y ↗
62. 10.1038/bjc.2017.43410.1038/bjc.2017.434 ↗
63. 10.1016/j.immuni.2013.07.01210.1016/j.immuni.2013.07.012 ↗
64. 10.1056/NEJMoa170968410.1056/NEJMoa1709684 ↗
65. 10.1016/S1470-2045(16)30498-310.1016/S1470-2045(16)30498-3 ↗
66. 10.1038/nature1429210.1038/nature14292 ↗
67. 10.1136/jitc-2019-00033710.1136/jitc-2019-000337 ↗
68. 10.3390/cancers1501031910.3390/cancers15010319 ↗
69. 10.3390/cancers1307162610.3390/cancers13071626 ↗
70. 10.1080/2162402X.2018.148497810.1080/2162402X.2018.1484978 ↗
71. 10.21873/anticanres.1335810.21873/anticanres.13358 ↗
72. 10.3389/fphy.2020.56961810.3389/fphy.2020.569618 ↗
73. 10.1038/s41598-020-80512-w10.1038/s41598-020-80512-w ↗
74. 10.1073/pnas.220070811910.1073/pnas.2200708119 ↗
75. 10.3390/cells1122365910.3390/cells11223659 ↗
76. 10.3390/vaccines1011181410.3390/vaccines10111814 ↗
77. 10.1161/01.ATV.0000181744.58265.6310.1161/01.ATV.0000181744.58265.63 ↗
78. 10.1038/ni.203510.1038/ni.2035 ↗
79. 10.1126/science.aaa497110.1126/science.aaa4971 ↗
80. 10.1016/j.immuni.2018.03.02310.1016/j.immuni.2018.03.023 ↗
81. 10.1038/s41467-020-15726-710.1038/s41467-020-15726-7 ↗
82. 10.1038/mt.2015.11510.1038/mt.2015.115 ↗
83. 10.1038/s41591-019-0499-y10.1038/s41591-019-0499-y ↗
84. 10.1002/advs.20190343810.1002/advs.201903438 ↗
85. 10.1088/1361-6463/aa5dbb10.1088/1361-6463/aa5dbb ↗
86. 10.1109/TRPMS.2018.280967310.1109/TRPMS.2018.2809673 ↗
87. 10.1080/2162402X.2020.185973110.1080/2162402X.2020.1859731 ↗
88. 10.1088/1361-6463/aab3ad10.1088/1361-6463/aab3ad ↗
89. 10.1073/pnas.050658010210.1073/pnas.0506580102 ↗
90. 10.1038/ng118010.1038/ng1180 ↗
91. 10.1101/gr.123930310.1101/gr.1239303 ↗
92. 10.1038/nmeth.333710.1038/nmeth.3337 ↗